Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis
The Clinical Respiratory Journal | Nov 17, 2017
Abdel-Rahman O - This study was carried out to determine the potential clinical and biological predictive markers of survival in pre-treated advanced NSCLC patients treated with three PD-(L)1 inhibitors (nivolumab, pembrolizumab, and atezolizumab). In previously treated NSCLC patients, smoking history and EGFR status were shown to be helpful in predicting the performance of PD-(L)1 inhibitors versus docetaxel.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
